Suppr超能文献

可待因重新分类对滥用的影响:对澳大利亚最大中毒控制中心来电的回顾性研究

The impact of codeine re-scheduling on misuse: a retrospective review of calls to Australia's largest poisons centre.

作者信息

Cairns Rose, Brown Jared A, Buckley Nicholas A

机构信息

New South Wales Poisons Information Centre, The Children's Hospital at Westmead, Westmead, NSW, Australia.

Clinical Pharmacology and Toxicology Research Group, Discipline of Pharmacology, School of Medical Sciences, Sydney Medical School, The University of Sydney, NSW, Australia.

出版信息

Addiction. 2016 Oct;111(10):1848-53. doi: 10.1111/add.13450. Epub 2016 Jun 14.

Abstract

BACKGROUND AND AIMS

Codeine is the most commonly used opioid in the world, and is available over the counter (OTC) in many countries, including Australia. Several countries are reconsidering codeine's OTC status due to concerns over addiction and misuse, with serious morbidity and mortality being reported. Australia's Therapeutic Goods Administration restricted codeine containing analgesics to 'Pharmacist Only' in 2010, and has recently been considering further up-scheduling to make codeine 'Prescription Only'. This paper estimated Australian trends of codeine misuse over the past 12 years, and examined whether trends changed following previous rescheduling efforts in 2010.

DESIGN

A retrospective review of calls regarding codeine misuse made to the New South Wales Poisons Information Centre (NSWPIC, Australia's largest poisons centre), 2004-15. Joinpoint software was used to quantify the average annual change in calls, and whether there was a significant change in trend at any time, including following rescheduling.

SETTING

Australia.

PARTICIPANTS

Four hundred patients about whom a call was made to the NSWPIC.

MEASURES

Calls per year, patient age, gender, tablets taken per day, formulation used, symptom disposition.

FINDINGS

The NSWPIC database contained 400 cases of codeine combination analgesic misuse from 2004 to 2015. Joinpoint analysis showed that the frequency of cases increased significantly from 2004 to 2015, with an average annual percentage change (AAPC) of 19.5% [95% confidence interval (CI) = 13.8-25.5% P < 0.0001] for paracetamol/codeine and 17.9% (95% CI = 7.9-28.9%, P < 0.01) for ibuprofen/codeine. No significant change in trend was seen at any time, including following 2010 rescheduling. The median age of patients was 34 and 27 years for paracetamol/codeine and ibuprofen/codeine cases, respectively. Gender distribution was approximately equal. Clinical features reported were consistent with codeine, paracetamol and ibuprofen toxicity.

CONCLUSIONS

Misuse of codeine combination products appears to be increasing in Australia. Limited rescheduling in 2010 failed to curb this increase.

摘要

背景与目的

可待因是全球最常用的阿片类药物,在包括澳大利亚在内的许多国家都可在柜台购买(非处方药)。由于对成瘾和滥用问题的担忧,并已有严重发病和死亡情况的报告,几个国家正在重新考虑可待因的非处方药地位。澳大利亚治疗用品管理局在2010年将含可待因的镇痛药限制为“仅药剂师可售”,并且最近一直在考虑进一步提高管控级别,使可待因成为“仅凭处方购买”药物。本文估计了澳大利亚过去12年可待因滥用的趋势,并研究了在2010年之前进行的重新安排之后趋势是否发生了变化。

设计

对2004年至2015年期间向新南威尔士州毒物信息中心(NSWPIC,澳大利亚最大的毒物中心)拨打的有关可待因滥用的电话进行回顾性分析。使用Joinpoint软件对电话数量的年均变化进行量化,以及在任何时间(包括重新安排之后)趋势是否有显著变化。

地点

澳大利亚。

参与者

向NSWPIC拨打过电话的400名患者。

测量指标

每年的电话数量、患者年龄、性别、每天服用的片剂数量、使用的剂型、症状处理情况。

结果

NSWPIC数据库包含2004年至2015年期间400例可待因复方镇痛药滥用病例。Joinpoint分析显示,从2004年到2015年病例数量显著增加,对乙酰氨基酚/可待因的年均百分比变化(AAPC)为19.5%[95%置信区间(CI)=13.8 - 25.5%,P < 0.0001],布洛芬/可待因的年均百分比变化为17.9%(95%CI = 7.9 - 28.9%,P < 0.01)。在任何时间(包括2010年重新安排之后)均未观察到趋势有显著变化。对乙酰氨基酚/可待因和布洛芬/可待因病例的患者中位年龄分别为34岁和27岁。性别分布大致相等。报告的临床特征与可待因、对乙酰氨基酚和布洛芬毒性相符。

结论

在澳大利亚,可待因复方产品的滥用似乎在增加。2010年有限的重新安排未能遏制这种增长。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验